Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 86Ovarian Neoplasms 33Breast Neoplasms 29Carcinoma, Non-Small-Cell Lung 28Colonic Neoplasms 23Rectal Neoplasms 21Fallopian Tube Neoplasms 17Neoplasms 16Neoplasm Metastasis 13Carcinoma, Hepatocellular 13Glioblastoma 11Lung Neoplasms 10Brain Neoplasms 8Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Intestinal Neoplasms 5Gastrointestinal Neoplasms 5Digestive System Neoplasms 5Brenner Tumor 5Recurrence 4Peritoneal Neoplasms 4Glioma 4Carcinoma, Ovarian Epithelial 4Adenocarcinoma of Lung 4Rectal Diseases 3Non-Squamous Non-Small Cell Lung Cancer 3Liver Neoplasms 3Intestinal Diseases 3Gastrointestinal Diseases 3

Interventions

taxane 1liposomal doxorubicin 1Sorafenib 1Paclitaxel 1Docetaxel 1Cisplatin 1Biosimilar Pharmaceuticals 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Vaccinia × Bevacizumab × Clear all
NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

Genelux Corporation

Phase 3 Recruiting
186 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡